With about 5.4 million people suffering from Alzheimer's disease in the U.S. and 44 million worldwide, and with populations in developed countries living longer, the search for effective therapies is becoming ever more urgent. Analysts at J.P. Morgan call AD "one of the most attractive potential new categories in major pharma and biotech," with the potential for more than $10 billion in peak sales for a drug that works. A new report by the firm pegs "a number of key catalysts" this year, and anticipates that investors' focus on AD will increase as 2016 wears on.